

Qifeng Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7456972/publications.pdf>

Version: 2024-02-01

58
papers

5,437
citations

126858

33
h-index

133188

59
g-index

62
all docs

62
docs citations

62
times ranked

6520
citing authors

#	ARTICLE	IF	CITATIONS
1	Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5652-5657.	0.8	956
2	Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. <i>Seminars in Cancer Biology</i> , 2020, 60, 14-27.	4.3	460
3	VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging $\text{CD}44^{\text{v}6}$ -Positive Osteoclast Progenitors. <i>Cancer Cell</i> , 2011, 20, 701-714.	7.7	445
4	MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer. <i>Cancer Cell</i> , 2009, 15, 9-20.	7.7	377
5	circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. <i>Molecular Therapy</i> , 2019, 27, 1638-1652.	3.7	298
6	Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. <i>Cancer Cell</i> , 2021, 39, 423-437.e7.	7.7	253
7	Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. <i>Nature Cell Biology</i> , 2017, 19, 1274-1285.	4.6	218
8	LncRNA "CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA "215. <i>Journal of Cellular Physiology</i> , 2019, 234, 9105-9117.	2.0	189
9	SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. <i>Cell Death and Differentiation</i> , 2019, 26, 843-859.	5.0	130
10	MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. <i>Cell Death and Disease</i> , 2018, 9, 14.	2.7	124
11	circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. <i>Oncogene</i> , 2019, 38, 6850-6866.	2.6	106
12	Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28. <i>Theranostics</i> , 2021, 11, 3932-3947.	4.6	95
13	Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem "like Cell Traits in Breast Cancer. <i>Cancer Research</i> , 2015, 75, 3672-3680.	0.4	76
14	circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway. <i>Molecular Therapy</i> , 2022, 30, 415-430.	3.7	70
15	DLC1-dependent parathyroid hormone "like hormone inhibition suppresses breast cancer bone metastasis. <i>Journal of Clinical Investigation</i> , 2014, 124, 1646-1659.	3.9	67
16	A genotyping system capable of simultaneously analyzing > 1000 single nucleotide polymorphisms in a haploid genome. <i>Genome Research</i> , 2005, 15, 276-283.	2.4	63
17	The anticancer effect of Huaier (Review). <i>Oncology Reports</i> , 2015, 34, 12-21.	1.2	63
18	Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 120-131.	1.5	62

#	ARTICLE	IF	CITATIONS
19	Targeting the circBMP2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 347-361.	2.3	62
20	A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. <i>Cell Death and Disease</i> , 2018, 9, 563.	2.7	59
21	Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue. <i>Diagnostic Pathology</i> , 2010, 5, 38.	0.9	57
22	Hedgehog pathway is involved in nitidine chloride induced inhibition of epithelial-mesenchymal transition and cancer stem cells-like properties in breast cancer cells. <i>Cell and Bioscience</i> , 2016, 6, 44.	2.1	57
23	MicroRNA-99a inhibits tumor aggressive phenotypes through regulating HOXA1 in breast cancer cells. <i>Oncotarget</i> , 2015, 6, 32737-32747.	0.8	53
24	Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377a-3p/HOXC6 signaling pathway. <i>Journal of Cellular Physiology</i> , 2019, 234, 13303-13317.	2.0	51
25	CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation. <i>Oncogene</i> , 2021, 40, 2756-2771.	2.6	50
26	Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies. <i>British Journal of Cancer</i> , 2021, 125, 1056-1067.	2.9	50
27	Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and l ^{nc} Np63. <i>Nature Communications</i> , 2021, 12, 5232.	5.8	50
28	EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. <i>Nature Communications</i> , 2019, 10, 5033.	5.8	42
29	circHMCU Promotes Proliferation and Metastasis of Breast Cancer by Sponging the let-7 Family. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 518-533.	2.3	40
30	Huaier extract suppresses breast cancer via regulating tumor-associated macrophages. <i>Scientific Reports</i> , 2016, 6, 20049.	1.6	39
31	The Oncogene Metadherin Modulates the Apoptotic Pathway Based on the Tumor Necrosis Factor Superfamily Member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2013, 288, 9396-9407.	1.6	37
32	Genetic Ablation of Metadherin Inhibits Autochthonous Prostate Cancer Progression and Metastasis. <i>Cancer Research</i> , 2014, 74, 5336-5347.	0.4	37
33	LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. <i>Cellular Signalling</i> , 2020, 68, 109536.	1.7	35
34	Post-Mastectomy Radiotherapy for Breast Cancer Patients with T1-T2 and 1-3 Positive Lymph Nodes: a Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e81765.	1.1	33
35	Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC. <i>Scientific Reports</i> , 2019, 9, 236.	1.6	29
36	53 BP 1 suppresses epithelial-mesenchymal transition by downregulating ZEB 1 through micro RNA hsa-miR-429 in breast cancer. <i>Cancer Science</i> , 2015, 106, 982-989.	1.7	28

#	ARTICLE	IF	CITATIONS
37	Huaier Extract Induces Autophagic Cell Death by Inhibiting the mTOR/S6K Pathway in Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0131771.	1.1	27
38	Huaier Suppresses Breast Cancer Progression via linc00339/miR-4656/CSNK2B Signaling Pathway. <i>Frontiers in Oncology</i> , 2019, 9, 1195.	1.3	27
39	A novel long non-coding RNA AC073352.1 promotes metastasis and angiogenesis via interacting with YBX1 in breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 670.	2.7	26
40	Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells. <i>Oncotarget</i> , 2016, 7, 26003-26015.	0.8	23
41	PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer. <i>Cancer Cell International</i> , 2021, 21, 13.	1.8	17
42	Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer. <i>International Journal of Oncology</i> , 2015, 46, 1286-1294.	1.4	15
43	MTDH Promotes Intestinal Inflammation by Positively Regulating TLR Signalling. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2103-2117.	0.6	15
44	LINC01977 Promotes Breast Cancer Progression and Chemoresistance to Doxorubicin by Targeting miR-212-3p/GOLM1 Axis. <i>Frontiers in Oncology</i> , 2021, 11, 657094.	1.3	14
45	Impact of histotypes on preferential organ-specific metastasis in triple-negative breast cancer. <i>Cancer Medicine</i> , 2020, 9, 872-881.	1.3	13
46	Relationship between Upper Extremity Lymphatic Drainage and Sentinel Lymph Nodes in Patients with Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	12
47	Identification of DGUOK-AS1 as a Prognostic Factor in Breast Cancer by Bioinformatics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1092.	1.3	12
48	DGUOK-AS1 acts as a tumor promoter through regulating miR-204-5p/IL-11 axis in breast cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1079-1091.	2.3	12
49	<p>>Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer</p><p>>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3535-3545.	2.0	11
50	Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer. <i>Disease Markers</i> , 2021, 2021, 1-9.	0.6	10
51	Precise intraoperative sentinel lymph node biopsies guided by lymphatic drainage in breast cancer. <i>Oncotarget</i> , 2017, 8, 63064-63072.	0.8	9
52	Exosomal non-coding RNAs: Emerging roles in bilateral communication between cancer cells and macrophages. <i>Molecular Therapy</i> , 2022, 30, 1036-1053.	3.7	8
53	Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer. <i>Cancer Medicine</i> , 2021, 10, 7877-7892.	1.3	6
54	CircEIF3H-IGF2BP2-HuR scaffold complex promotes TNBC progression via stabilizing HSPD1/RBM8A/G3BP1 mRNA. <i>Cell Death Discovery</i> , 2022, 8, 261.	2.0	5

#	ARTICLE	IF	CITATIONS
55	Huaier Induces Immunogenic Cell Death Via CircCLASP1/PKR/eIF2 γ Signaling Pathway in Triple Negative Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
56	The E3 Ligase TRIM4 Facilitates SET Ubiquitin α -Mediated Degradation to Enhance ER α Action in Breast Cancer. <i>Advanced Science</i> , 2022, 9, .	5.6	4
57	Oncological Minimally Invasive Surgery. <i>Journal of Oncology</i> , 2019, 2019, 1-2.	0.6	2
58	A Novel lncRNA Panel for Risk Stratification and Immune Landscape in Breast Cancer Patients. <i>International Journal of General Medicine</i> , 0, Volume 15, 5253-5272.	0.8	0